Celadon Pharmaceuticals
Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company dedicated to developing breakthrough cannabis-based medicines. Founded in 2018 following the legalization of cannabis-based medicinal products in the UK, the company operates a 100,000 sq ft EU-GMP standard facility for cultivation, extraction, and manufacturing. Its mission is to improve quality of life for patients through innovative cannabis medicines, with a primary focus on chronic pain. The company is publicly listed on the AIM market of the London Stock Exchange and has a strong focus on clinical trials, R&D, and regulatory compliance. It is one of a limited number of companies globally with approvals to cultivate and manufacture EU-GMP grade high-THC medicinal cannabis, and is understood to be the first for high-THC API in the UK since medicinal cannabis was legalised in 2018.
Industries
Nr. of Employees
small (1-50)
Celadon Pharmaceuticals
London, England, United Kingdom, Europe
Products
GMP botanical active pharmaceutical ingredient (API)
Pharmaceutical‑grade botanical API produced under EU‑GMP conditions for use in prescription medicines and clinical research.
GMP botanical active pharmaceutical ingredient (API)
Pharmaceutical‑grade botanical API produced under EU‑GMP conditions for use in prescription medicines and clinical research.
Services
On‑site production of pharmaceutical‑grade botanical API under EU‑GMP standards, with third‑party analytical validation and logistics for commercial and clinical customers.
Design and operational support for large‑scale clinical trials of botanical medicinal products, including regulatory submissions, supply of GMP product, logistics to trial sites, and integration of inhalation devices and mobile apps for controlled dosing and real‑time data capture.
Collaborative research and supply agreements with biopharma partners to provide botanical API, co-develop delivery technologies and support progression of licensed medicinal candidates.
On‑site capture of cultivation and production data via sensor networks and IoT, with analytic reporting to identify optimal growing conditions and inform economic and feasibility planning.
On‑site production of pharmaceutical‑grade botanical API under EU‑GMP standards, with third‑party analytical validation and logistics for commercial and clinical customers.
Design and operational support for large‑scale clinical trials of botanical medicinal products, including regulatory submissions, supply of GMP product, logistics to trial sites, and integration of inhalation devices and mobile apps for controlled dosing and real‑time data capture.
Collaborative research and supply agreements with biopharma partners to provide botanical API, co-develop delivery technologies and support progression of licensed medicinal candidates.
On‑site capture of cultivation and production data via sensor networks and IoT, with analytic reporting to identify optimal growing conditions and inform economic and feasibility planning.
Expertise Areas
- Pharmaceutical GMP manufacturing of botanical APIs
- Controlled‑environment agriculture for pharmaceutical crops
- Clinical trial management and CTIMP execution
- Analytical testing and third‑party API validation
Key Technologies
- Hydroponic cultivation systems
- Micro‑zoned environmental sensor networks
- IoT track‑and‑trace and data integration systems
- EU/GMP manufacturing processes for APIs
News & Updates
The company’s indoor hydroponic facility completes its eighth harvest, supporting its EU-GMP application.
The company is approved for GMP manufacturing of cannabis API, a milestone in UK cannabis regulation.
UK regulators update the cultivation and production license, enabling commercial supply.
Feature in The Guardian highlighting Celadon's pioneering role in UK medical cannabis regulation.
Financial Times reports on Celadon's achievement in gaining commercial sales rights.
Celadon is one of the few companies globally with EU-GMP approval for pharmaceutical cannabis API production.
The company’s indoor hydroponic facility completes its eighth harvest, supporting its EU-GMP application.
The company is approved for GMP manufacturing of cannabis API, a milestone in UK cannabis regulation.
UK regulators update the cultivation and production license, enabling commercial supply.
Feature in The Guardian highlighting Celadon's pioneering role in UK medical cannabis regulation.
Financial Times reports on Celadon's achievement in gaining commercial sales rights.
Celadon is one of the few companies globally with EU-GMP approval for pharmaceutical cannabis API production.